TY - JOUR
T1 - Amyloid-beta and depression in healthy older adults
T2 - A systematic review
AU - Harrington, Karra D.
AU - Lim, Yen Ying
AU - Gould, Emma
AU - Maruff, Paul
PY - 2015/1/20
Y1 - 2015/1/20
N2 - Objective: Depression has been shown to be a risk factor for Alzheimer's disease (AD), and in older adults may provide a marker for the beginning of the prodromal phase of AD. The purpose of this systematic review is to examine the relationship between amyloid-β (Aβ), a key biomarker of AD, and depression in older adults. Method: The literature search was limited to studies conducted from 2006 to 2014 that were published in English in peer-reviewed journals. Studies were selected if they included a group of older adults who either met established criteria for Major Depressive Disorder or Dysthymia; or were assessed for depressive symptoms on a standardised measure. Studies were also required to include an outcome variable that was a direct measure of Aβ levels in either blood or cerebrospinal fluid (CSF) samples, or via neuroimaging techniques such as positron emission tomography (PET). Results: Nineteen studies were identified, 15 of which found significant differences in Aβ levels between depressed and non-depressed older adults. However, studies were limited by their cross-sectional design, reliance on blood-based measures of Aβ, and potential sample bias. Conclusions: Future investigations should consider prospective longitudinal design using neuroimaging and CSF measures of Aβ.
AB - Objective: Depression has been shown to be a risk factor for Alzheimer's disease (AD), and in older adults may provide a marker for the beginning of the prodromal phase of AD. The purpose of this systematic review is to examine the relationship between amyloid-β (Aβ), a key biomarker of AD, and depression in older adults. Method: The literature search was limited to studies conducted from 2006 to 2014 that were published in English in peer-reviewed journals. Studies were selected if they included a group of older adults who either met established criteria for Major Depressive Disorder or Dysthymia; or were assessed for depressive symptoms on a standardised measure. Studies were also required to include an outcome variable that was a direct measure of Aβ levels in either blood or cerebrospinal fluid (CSF) samples, or via neuroimaging techniques such as positron emission tomography (PET). Results: Nineteen studies were identified, 15 of which found significant differences in Aβ levels between depressed and non-depressed older adults. However, studies were limited by their cross-sectional design, reliance on blood-based measures of Aβ, and potential sample bias. Conclusions: Future investigations should consider prospective longitudinal design using neuroimaging and CSF measures of Aβ.
KW - Alzheimer's disease
KW - Amyloid-β
KW - Depression
UR - https://www.scopus.com/pages/publications/84919432546
U2 - 10.1177/0004867414557161
DO - 10.1177/0004867414557161
M3 - Review Article
C2 - 25414381
AN - SCOPUS:84919432546
SN - 0004-8674
VL - 49
SP - 36
EP - 46
JO - Australian and New Zealand Journal of Psychiatry
JF - Australian and New Zealand Journal of Psychiatry
IS - 1
ER -